Avidity Biosciences, Inc. Common Stock
RNA Real Time Price USDRecent trades of RNA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RNA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
RNA Revenue by Segment or Geography
New patents grants
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Apr. 01, 2025
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 25, 2025
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 03, 2024
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Oct. 01, 2024
-
Patent Title: Anti-transferrin receptor antibody-pmo conjugates for inducing dmd exon 44 skipping Aug. 27, 2024
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Aug. 27, 2024
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 20, 2024
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jul. 30, 2024
-
Patent Title: Una amidites and uses thereof Jun. 11, 2024
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jun. 04, 2024
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Feb. 27, 2024
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 16, 2024
-
Patent Title: Anti-transferrin receptor antibodies and uses thereof Dec. 05, 2023
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Aug. 01, 2023
-
Patent Title: Compositions and methods of treating muscle dystrophy Jul. 25, 2023
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 21, 2023
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 14, 2023
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 14, 2023
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jan. 17, 2023
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 17, 2023
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 13, 2022
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Nov. 15, 2022
-
Patent Title: Compositions and methods of treating muscle dystrophy Sep. 20, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 02, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jun. 21, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Apr. 26, 2022
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 22, 2022
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 15, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Nov. 23, 2021
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 07, 2021
-
Patent Title: Anti-transferrin receptor antibodies and uses thereof Jun. 08, 2021
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping May. 04, 2021
-
Patent Title: Anti-transferrin receptor antibodies and uses thereof Feb. 09, 2021
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 05, 2021
-
Patent Title: Egfr nucleic acids and uses thereof Dec. 29, 2020
-
Patent Title: Kras nucleic acids and uses thereof Dec. 08, 2020
-
Patent Title: Beta-catenin nucleic acids and uses thereof Nov. 24, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Oct. 13, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 29, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 04, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Nov. 26, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to RNA
Recent picks made for RNA stock on CNBC
ETFs with the largest estimated holdings in RNA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $RNA stock a Buy, Sell, or Hold?
- What is the price target for $RNA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $RNA stock?
- Who owns the most shares of $RNA stock?
- What funds own $RNA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RNA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.